The viral vector production market was valued for $1.1 billion in 2022 and is estimated to reach $6.1 billion by 2032, exhibiting a CAGR of 18.8% from 2023 to 2032.
Viral vectors are tools used in gene therapy and vaccine development to deliver genetic material into target cells. They are derived from naturally occurring viruses that have been modified to remove their disease-causing ability while retaining their ability to efficiently enter cells and deliver the desired genetic material. Viral vectors are designed to carry and introduce therapeutic genes, such as missing or mutated genes, into the cells of patients.
They act as delivery vehicles, transporting the genetic material to the target cells where it may be expressed and produce the desired therapeutic effect. Several types of viruses are commonly used as viral vectors, Including adenoviruses, adeno-associated viruses (AAV), lentiviruses, retroviruses, and others. Each type of viral vector has unique characteristics and is selected on the basis of factors such as the target cell type, the desired duration of gene expression and others.
The viral vector production process involves modifying the viral genome to remove disease-causing elements and inserting the therapeutic gene of interest. The modified viral vector is then produced in enormous quantities through cell culture or other manufacturing methods. Quality control measures are implemented to ensure the safety, potency, and purity of the viral vector product.
The Increase in prevalence of genetic disorders worldwide is a significant driving force behind the growth of the viral vector production market. Genetic conditions such as muscular dystrophy, cystic fibrosis, and hemophilia impact a large number of individuals globally. For instance, National Hemophilia Foundation (2023) there are between 30,000 to 33,000 people who live with hemophilia in the U.S. Gene therapy offers promising potential for treatment of these disorders, providing the possibility of a cure or long-term treatment options.
Moreover, viral vectors play a crucial role in gene therapy as they act as carriers, delivering therapeutic genes into the targeted cells to correct the underlying genetic defects. The growth in awareness and knowledge about gene therapy among healthcare professionals and patients has contributed to the rise in demand for viral vector production.
In addition, the global Incidence of cancer has been on the rise, with a substantial number of new cases being diagnosed annually. This alarming trend has spurred significant interest in innovative treatment modalities, and viral vectors have emerged as pivotal components in gene therapy strategies for combating cancer. These specialized vectors have the ability to transport therapeutic genes or induce modifications in target cells, thereby amplifying immune responses against cancerous cells.
In addition, viral vector platforms play a critical role in the advancement of oncolytic viral therapies, which utilize viruses to directly target and eradicate cancer cells. The Increase in demand for effective cancer treatments serves as a driving force behind the growth in need for viral vectors and their production. Furthermore, the COVID-19 pandemic has led to a significant rise in viral vector production for vaccine development.
Viral vectors, such as adenoviruses, have been utilized as a platform for the development of COVID-19 vaccines. These vectors are engineered to carry the genetic material of the SARS-CoV-2 spike protein, stimulating an immune response in vaccinated individuals. The urgent need for effective vaccines to combat the global health crisis has accelerated the production of viral vectors and thus contributed significantly to the growth of the market.
However, the viral vector production market faces certain restraints that may impede its growth and development. One significant restraint is the excessive cost associated with viral vector production. The manufacturing process requires substantial upfront capital investment, specialized infrastructure, and skilled personnel. In addition, the use of expensive raw materials and quality control measures further escalates production costs. These high costs may limit accessibility and affordability of gene therapies and viral vector-based vaccines, hindering the wider adoption and market growth.
On the contrary, the viral vector production market presents significant opportunities for growth and innovation. The Increase in adoption of gene therapies and viral vector-based vaccines, coupled with the expanding pipeline of promising candidates, fuels the demand for viral vectors. Advancements in vector engineering, manufacturing technologies, and process optimization create opportunities for more efficient and cost-effective production.
Furthermore, developing regions present significant opportunities for growth in the viral vector production market. Rise in healthcare expenditures, developing healthcare infrastructure, government initiatives and support for treatment of complex diseases is further anticipated to boost the demand for viral vector production in this region.
The global viral vector production market is segmented based on viral vector type, indication, application, end user, and region. On the basis of viral vector type, the market is categorized into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral, and other viral vectors. On the basis of indication, it is segregated into cancer, genetic disorders, infectious diseases, and other diseases. On the basis of application, it is bifurcated into gene therapy, and vaccinology.
On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). Major players that operate in the market Include Andelyn Biosciences, Charles River Laboratories, Danaher Corporation., FinVector Oy, Lonza, Novartis AG, Oxford Biomedica plc, Takara Holdings Inc., Thermo Fisher Scientific Inc. and Avid Bioservices, Inc.
Viral vectors are tools used in gene therapy and vaccine development to deliver genetic material into target cells. They are derived from naturally occurring viruses that have been modified to remove their disease-causing ability while retaining their ability to efficiently enter cells and deliver the desired genetic material. Viral vectors are designed to carry and introduce therapeutic genes, such as missing or mutated genes, into the cells of patients.
They act as delivery vehicles, transporting the genetic material to the target cells where it may be expressed and produce the desired therapeutic effect. Several types of viruses are commonly used as viral vectors, Including adenoviruses, adeno-associated viruses (AAV), lentiviruses, retroviruses, and others. Each type of viral vector has unique characteristics and is selected on the basis of factors such as the target cell type, the desired duration of gene expression and others.
The viral vector production process involves modifying the viral genome to remove disease-causing elements and inserting the therapeutic gene of interest. The modified viral vector is then produced in enormous quantities through cell culture or other manufacturing methods. Quality control measures are implemented to ensure the safety, potency, and purity of the viral vector product.
The Increase in prevalence of genetic disorders worldwide is a significant driving force behind the growth of the viral vector production market. Genetic conditions such as muscular dystrophy, cystic fibrosis, and hemophilia impact a large number of individuals globally. For instance, National Hemophilia Foundation (2023) there are between 30,000 to 33,000 people who live with hemophilia in the U.S. Gene therapy offers promising potential for treatment of these disorders, providing the possibility of a cure or long-term treatment options.
Moreover, viral vectors play a crucial role in gene therapy as they act as carriers, delivering therapeutic genes into the targeted cells to correct the underlying genetic defects. The growth in awareness and knowledge about gene therapy among healthcare professionals and patients has contributed to the rise in demand for viral vector production.
In addition, the global Incidence of cancer has been on the rise, with a substantial number of new cases being diagnosed annually. This alarming trend has spurred significant interest in innovative treatment modalities, and viral vectors have emerged as pivotal components in gene therapy strategies for combating cancer. These specialized vectors have the ability to transport therapeutic genes or induce modifications in target cells, thereby amplifying immune responses against cancerous cells.
In addition, viral vector platforms play a critical role in the advancement of oncolytic viral therapies, which utilize viruses to directly target and eradicate cancer cells. The Increase in demand for effective cancer treatments serves as a driving force behind the growth in need for viral vectors and their production. Furthermore, the COVID-19 pandemic has led to a significant rise in viral vector production for vaccine development.
Viral vectors, such as adenoviruses, have been utilized as a platform for the development of COVID-19 vaccines. These vectors are engineered to carry the genetic material of the SARS-CoV-2 spike protein, stimulating an immune response in vaccinated individuals. The urgent need for effective vaccines to combat the global health crisis has accelerated the production of viral vectors and thus contributed significantly to the growth of the market.
However, the viral vector production market faces certain restraints that may impede its growth and development. One significant restraint is the excessive cost associated with viral vector production. The manufacturing process requires substantial upfront capital investment, specialized infrastructure, and skilled personnel. In addition, the use of expensive raw materials and quality control measures further escalates production costs. These high costs may limit accessibility and affordability of gene therapies and viral vector-based vaccines, hindering the wider adoption and market growth.
On the contrary, the viral vector production market presents significant opportunities for growth and innovation. The Increase in adoption of gene therapies and viral vector-based vaccines, coupled with the expanding pipeline of promising candidates, fuels the demand for viral vectors. Advancements in vector engineering, manufacturing technologies, and process optimization create opportunities for more efficient and cost-effective production.
Furthermore, developing regions present significant opportunities for growth in the viral vector production market. Rise in healthcare expenditures, developing healthcare infrastructure, government initiatives and support for treatment of complex diseases is further anticipated to boost the demand for viral vector production in this region.
The global viral vector production market is segmented based on viral vector type, indication, application, end user, and region. On the basis of viral vector type, the market is categorized into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral, and other viral vectors. On the basis of indication, it is segregated into cancer, genetic disorders, infectious diseases, and other diseases. On the basis of application, it is bifurcated into gene therapy, and vaccinology.
On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). Major players that operate in the market Include Andelyn Biosciences, Charles River Laboratories, Danaher Corporation., FinVector Oy, Lonza, Novartis AG, Oxford Biomedica plc, Takara Holdings Inc., Thermo Fisher Scientific Inc. and Avid Bioservices, Inc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the viral vector production market analysis from 2022 to 2032 to identify the prevailing viral vector production market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the viral vector production market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report Includes the analysis of the regional as well as global viral vector production market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Indication
- Cancer
- Genetic Disorders
- Infectious Diseases
- Other Diseases
By Application
- Gene Therapy
- Vaccinology
By Viral Vector Type
- Adenoviral Vectors
- Lentiviral Vectors
- Retroviral Vectors
- Adeno-Associated Viral Vectors
- Other Viral Vectors
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Andelyn Biosciences
- Avid Bioservices, Inc.
- Charles River Laboratories
- Danaher Corporation
- FinVector Oy
- Lonza
- Novartis AG
- Oxford Biomedica
- TAKARA HOLDINGS Inc.
- Thermo Fisher Scientific Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE
CHAPTER 5: VIRAL VECTOR PRODUCTION MARKET, BY INDICATION
CHAPTER 6: VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION
CHAPTER 7: VIRAL VECTOR PRODUCTION MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
The viral vector production market is likely to experience a significant growth rate of 18.8% from 2023-2032 owing to increasing market demand from diagnostic and biotech sector.A viral vector is a genetically engineered virus that is used to deliver genetic material into target cells for various applications in gene therapy and biomedical research. There are several types of viral vectors, including adenoviruses, lentiviruses, retroviruses, adeno-associated viruses (AAV), herpes simplex viruses (HSV), baculoviruses, poxviruses, and vesicular stomatitis viruses (VSV). Viral vectors find applications in gene therapy, where they deliver therapeutic genes to treat genetic disorders and diseases. Moreover, they are used in vaccine development to deliver antigen genes, stimulating an immune response.
Key factors driving the growth of the viral vector production market is attributed to the rise in prevalence of cancer, infectious diseases, and genetic disorders, increase in demand and awareness for gene therapy and surge in number of strategies adopted by market key players. The increasing number of clinical trials for gene therapy and viral vectors is also driving the demand for production facilities and services of viral vectors.
Pharmaceutical companies and research organizations are conducting extensive studies to evaluate the safety and effectiveness of gene therapies, necessitating a substantial supply of viral vectors. This surge in demand is pushing the growth of the viral vector production market as more facilities are needed to meet the requirements of these trials, which is boosting the growth of the market.
In addition, the rising incidence of genetic disorders and cancer worldwide has led to a growing demand for gene therapies. Disorders like muscular dystrophy, hemophilia, and certain types of cancers can potentially benefit from gene therapy treatments which require viral vectors for development. As a result, there is a need for large-scale production of viral vectors to support gene therapy clinical trials and commercialization, which is further boosting the market growth.
Furthermore, the collaborations and partnerships observed in the viral vector production market present a significant opportunity for the key players in the market. Academic institutions, biopharmaceutical companies, and contract manufacturing organizations (CMOs) are forming alliances to drive innovation, enhance production capabilities, and capitalize on the growing demand for viral vectors. These collaborations foster the exchange of best practices and allow for the implementation of advanced manufacturing technologies.
Furthermore, collaborations enable risk-sharing among the involved parties, as the costs and expertise required for viral vector production may be substantial, thereby increasing investments in viral vector manufacturing. Such collaborations and partnerships are anticipated to drive the market during the forecast period.
Also, the costs involved in establishing and maintaining a viral vector production facility can be considerable. Collaborative efforts allow organizations to share the financial burden, making it more feasible to invest in state-of-the-art infrastructure, equipment, and technologies required for large-scale vector production. This shared investment not only reduces the financial strain on individual participants but also allows them to access resources that might otherwise be beyond their reach. As a result, the overall capacity for viral vector manufacturing may be expanded, leading to increased availability and affordability of these critical components for gene therapy and vaccine development.
The global viral vector production market is segmented on the basis of viral vector type, indication, application, end user, and region. On the basis of viral vector type, the market is categorized into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral, and other types. On the basis of indication, it is segregated into cancer, genetic disorders, infectious diseases and other diseases.
- On the basis of application, it is bifurcated into gene therapy and vaccinology. Based on region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
For instance, in October 2022, Charles River Laboratories and Nanoscope Therapeutics, Inc., announced a collaboration which will leverage Charles River's extensive contract development and manufacturing (CDMO) services in both plasmid DNA and viral vectors to support Nanoscope's gene therapy initiatives.
Key Market Insights
- By viral vector type, the adeno-associated viral vectors segment was the highest revenue contributor to the market and is estimated to reach $2.0 million by 2032, with a CAGR of 18.5%. However, the lentiviral vectors segment is estimated to be the fastest-growing segment during the forecast period.
- By indication, the cancer segment dominated the global market. However, the genetic disorders segment is expected to be the fastest-growing segment during the forecast period.
- Based on application, the gene therapy segment was the highest revenue contributor to the market and is anticipated to grow at a fastest rate during the forecast period.
- Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period
Companies Mentioned
- Andelyn Biosciences
- Avid Bioservices, Inc.
- Charles River Laboratories
- Danaher Corporation
- FinVector Oy
- Lonza
- Novartis AG
- Oxford Biomedica
- TAKARA HOLDINGS INC.
- Thermo Fisher Scientific Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
